Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair. - 2The Quadrantid meteor shower peaks tonight, but will the full 'Wolf Moon' outshine the show?
- 310 Hints for a Fruitful New employee screening
- 4Ever Wonder What An EV Motorcycle Water Crossing Would Be Like? Here You Go
- 5Israel explores creation of int'l force with Greece, Cyprus to deter Turkey
- First foreign troop in new gang suppression force lands in Haiti to replace previous mission
- Former Israeli judge does not expect Netanyahu to be pardoned
- What is Fusarium graminearum, the fungus a Chinese scientist pleaded guilty to smuggling into the US?
- Satellite data reveals a huge solar storm in 2024 shrank Earth's protective plasma shield
- Vote in favor of the wide open action that revives your brain and soul!
- New nesting beach for birds at RSPB reserve
- Best Wellness Tracker Keep You On target
- At 72, Kathie Lee Gifford says aging isn’t what she expected. 'The golden years? It’s a lie.’
- Step by step instructions to Choose the Right Auto Crash Legal counselor for Your Case
